Nasdaq

CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis

BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that neflamapimod, ...
ALS News Today

Long-term air pollution exposure shows no clear link to ALS in UK study

A large U.K. study found no clear link between long-term air pollution exposure and ALS risk. The researchers analyzed ...
The Florida Times-Union

UK-Based Vesalic Limited Emerges from Stealth with Landmark Discovery of Potential Non-CNS Driver of Motor Neuron Diseases, including ALS, and Breakthrough Therapeutic and ...

Vesalic is pioneering a novel therapeutic to intercept and neutralise these toxins, potentially slowing or halting progression of monogenic and sporadic forms of ALS In addition, Vesalic has ...
Nasdaq

CervoMed's Neflamapimod Chosen For UK EXPERTS-ALS Platform

(RTTNews) - CervoMed Inc. (CRVO), announced that its investigational therapy Neflamapimod has been selected for inclusion in the UK EXPERTS-ALS platform, a clinical trial initiative designed to ...
Sarasota Herald-Tribune

UK-Based Vesalic Limited Emerges from Stealth with Landmark Discovery of Potential Non-CNS Driver of Motor Neuron Diseases, including ALS, and Breakthrough Therapeutic and ...

This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo in ALS patients, which is carried to the CNS, where it binds to and damages neurons ...